GlassScriptPhysician profile
Megan Meyer Hanner
NPI 1801090717
$2,306.67
in general payments reported to CMS, 2019-2025
27 companies · $630 in 2025
The $630 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.10 · 2020: $138 · 2021: $85.58 · 2022: $341 · 2023: $682 · 2024: $340 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.18 | 2022-2025 | |
| Lilly USA, LLC | $306.10 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $264.62 | 2022-2024 | |
| Medtronic, INC. | $248.59 | 2021-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Attain Command + Surevalve |
| Novo Nordisk INC | $226.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $165.59 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $142.25 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.13 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $78.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $46.73 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $46.30 | 2022-2025 | Belsomra, Steglatro, Capvaxive |
| Dexcom, INC. | $45.83 | 2022-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $44.99 | 2023-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $37.73 | 2022 | |
| Abbott Laboratories | $31.01 | 2023 | Freestyle Libre 3, Proclaim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $26.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.88 | 2020 | |
| Supernus Pharmaceuticals, INC. | $22.31 | 2019 | |
| Insulet Corporation | $20.37 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $19.51 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Amgen INC. | $17.30 | 2022 | |
| Amarin Pharma, INC. | $15.85 | 2022 | |
| Tonix Medicines, INC. | $14.75 | 2025 | Tonmya |
| Paratek Pharmaceuticals, INC. | $14.12 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $13.04 | 2020 | |
| Allergan, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Meyer Hanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.